As of Dec 8, 2018 Acadia Pharmaceuticals Inc (NASDAQ:ACAD) Sellers Declined Their Shorts By 2.01%

Big Money Sentiment increased to 1.22 in 2018 Q2. It has change of 0.33, from 2018Q1’s 0.89. The ratio improved due to ACADIA Pharmaceuticals Inc. positioning: 31 sold and 43 reduced. 35 funds acquired stakes and 55 increased stakes. Investors holded 119.37 million in 2018Q1 but now own 114.30 million shares or 4.25% less.
Natixis stated it has 0% of its capital in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Ameritas Investment Ptnrs invested in 0.01% or 8,124 shs. Sei Invs invested 0% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Fmr Lc has 0.03% invested in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). 18,618 are held by Bb&T Lc. Moreover, Deutsche Comml Bank Ag has 0.02% invested in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Orbimed Advisors Ltd holds 4.28 million shs or 0.78% of its capital. Earnest Prtn Lc invested in 4,400 shs. New York-based Pdt Ptnrs Limited Liability Corp has invested 0.4% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Legal & General Grp Public Ltd Com reported 0% stake. Great West Life Assurance Co Can has invested 0% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Aperio Group Limited Liability Com holds 16,586 shs. National Bank & Trust Of America De accumulated 741,340 shs. Regions Corporation invested 0% of its capital in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Riggs Asset Managment holds 0% of its capital in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) for 650 shs.

ACADIA Pharmaceuticals Inc. registered $22.65 million net activity with 1 insider buy and 0 insider sales since September 20, 2018.

Acadia Pharmaceuticals Inc (NASDAQ:ACAD) recorded a decrease of 2.01% in short interest. It was issued in December by FINRA the 15.85M short interest on ACAD. That’s 2.01% down from 16.17M shares. Acadia Pharmaceuticals Inc (NASDAQ:ACAD) has 1.71M shares average volume. It’ll cost 9 days for ACAD to restore its previous position. Acadia Pharmaceuticals Inc’s short interest float is 16.22%.

ACAD touched $18.21 during the last trading session after $0.7 change.ACADIA Pharmaceuticals Inc. has volume of 1.98M shares. Since December 8, 2017 ACAD has declined 62.95% and is downtrending. The stock underperformed the S&P500 by 78.57%.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders.The firm is worth $2.62 billion. The firm offers NUPLAZID for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.Last it reported negative earnings. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Ratings Coverage

Total analysts of 7 have positions in ACADIA Pharmaceuticals (NASDAQ:ACAD) as follows: 4 rated it a “Buy”, 0 with “Sell” and 3 with “Hold”. The positive are 57%. Since August 6, 2018 according to StockzIntelligence Inc ACADIA Pharmaceuticals has 10 analyst reports. The stock rating was maintained by Bank of America with “Buy” on Wednesday, October 10. On Friday, September 21 the firm earned “Overweight” rating by PiperJaffray. On Thursday, November 1 the rating was maintained by Cantor Fitzgerald with “Overweight”. On Thursday, August 9 the company was maintained by JMP Securities. On Tuesday, October 16 the stock of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) earned “Overweight” rating by Cantor Fitzgerald. The company rating was downgraded by PiperJaffray on Monday, August 6.

For more ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) news published briefly go to: Seekingalpha.com, Seekingalpha.com, Nasdaq.com, Benzinga.com or Seekingalpha.com. The titles are as follows: “Acadia Pharma files for shelf stock offering; shares down 7% after hours – Seeking Alpha” published on November 26, 2018, “Acadia: Poised To Turn – Seeking Alpha” on December 04, 2018, “Noteworthy ETF Outflows: XBI, ACAD, IONS, ARRY – Nasdaq” with a publish date: November 16, 2018, “7 Stocks To Watch For November 27, 2018 – Benzinga” and the last “ACADIA Pharmaceuticals prices equity offering – Seeking Alpha” with publication date: November 28, 2018.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.